Anticoagulation and heart failure

Current Cardiology Reports

Volumn 3, Issue 1, 2001, Pages 72-77

  Graham, Susan P ^a  

^a BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; REVIEW; THROMBOEMBOLISM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ASPIRIN; HEART FAILURE, CONGESTIVE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, LEFT; WARFARIN;

EID: 0035236457     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0013-1     Document Type: Article

References (31)

1. Gottdiener JS, Arnold AM, et al.: Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Amer Coll Cardiol 2000, 35:1628-1637.
2. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe convestive heart failure. Results of the Cooperative North Scandanavian Enalapril Survival Study (Consensus). N Engl J Med 1987, 1316:1424-1434.
3. Cleland JGF: Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997, 12:276-287.
4. Meade TW, Medical Research Council's Research Framework: Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998, 351:233-241.
5. Gorelick PB, Sacco RL, Smith DB, et al.: Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999, 281:1112-1119.
6. Latini R, Tognoni G, Maggioni AP, et al.: Clinical effects of early antiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. J Amer Coll Cardiol 2000, 35:1801-1807.
7. Leor J, Reicher-Reiss H, et al.: Aspirin and Mortality in patients treated with angiotensin-converting enzyme inhibitors. J Amer Coll Cardiol 1999, 33:1920-1925.
8. Al Khadra AS, Salem DN, et al.: Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998, 31:419-425.
9. Masotti G, Galanti G, et al.: Differential inhibition of prostacyclin production and platelet aggreation by aspirin. Lancet 1979, 314:1213-1216.
10. Davie AP, Love MP, et al.: Even low dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther 2000, 67:530-537.
11. Spaulding C, Chorbonnie B, Cohen-Solal A, et al.: Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation 1998, 98:757-765.
12. Guazzi M: Hemodynamic interaction of aspirin with enalapril. Circulation 1999, 100(25):e141.
13. Guazzi MD, Campodonico J, Celeste F, et al.: Antihypertensive efficacy of angiotensin converting enzyme inhibition and asprin counteraction. Clin Pharmacol Ther 1998, 63:79-86.
14. Hall D, Zeitler H, Rudolph W: Counteraction of the vasodilator effects of enalpril by aspirin in severe heart failure. J Amer Coll Cardiol 1992, 20:1549-1555.
15. Stys T, Lawson WE, et al.: Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Int Med 2000, 160:1409-1413.
16. Hall D: The aspirin-angiotensin-converting enzyme inhibitor tradeoff: To halve and halve not. J Amer Coll Cardiol 2000, 35:1808-1812.
17. Page J, Henry D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Inten Med 2000, 160:777-784.
18. Go AS, Hylek EM, et al.: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927-934.
19. Hart RG, Pearce LA, Rothbart RM, et al.: Stroke with itermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Amer Coll Cardiol 2000, 35:183-187.
20. Goldman ME, Pearce LA, Hart RG, et al.: Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation (SPAF-III) Study). J Am Soc Echocardio 1999, 12:1080-1087.
21. Lip GY, Gibbs C: Does heart failure confer a hypercoagulable state? Virchow's Triad Revisted. J Amer Coll Cardiol 1999, 33:1424-1426.
22. Katz SD, Marantz PR, Biasucci L, et al.: Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993, 126:141-146.
23. Sharma ND, McCullough PA, Philbin ED, Weaver WD: Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest 2000, 117:314-320.
24. Dunkman WB, Johnson GR, Carson PE, et al.: Incidence of thromboembolic events in congestive heart failure. Circulation 1993, 87:VI-94-VI-101.
25. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence of gender differences in the studies of left ventricular dysfunction trials. JACC 1997, 29:1074-1080.
26. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Amer J Med 1989, 87:144-151.
27. Hylek EM, Singer DE: Risk factors of intracranial hemorrhage in outpatients taking warfarin. Ann of Int Med 1994, 120:897-902.
28. The HOPE (Heart Outcomes Prevention Evaluation) Study Investigators: Effects of angiotensin converting enzyme - inhibitor, ramipril on cardiac vascular death, myocardial infarction and stroke in high-risk patients. N Engl J Med 2000, 342:145-153.
29. MacMahon S, Sharpe N, et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Amer Coll Cardiol 2000, 36:438-443.
30. Cokkinos DV, Toutouzas PK: Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS). Eur J Heart Fail 1999, 1:419-423.
31. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis of warfarin against recurrent venous thromboembolism. N Engl J Med 2000, 343:1953-1958.